• Clinical Insights: August 30, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval AltrenoTM (tretinoin) – August 24, 2018 – Ortho Dermatologics, one of the largest prescription dermatology healthcare businesses in the world, announced that the U.S. Food and Drug… Read more »

  • Clinical Insights: May 1, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval JynarqueTM (tolvaptan) – April 24, 2018 – Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces that the U.S. Food and Drug Administration (FDA) has approved JynarqueTM (tolvaptan) as… Read more »

  • Clinical Insights: February 13, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Biktarvy® (bictegravir, emtricitabine and tenofovir alafenamide) – February 7, 2018 – Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Biktarvy®… Read more »

  • Clinical Insights: July 28, 2017

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Vosevi™ (sofosbuvir/velpatasvir/voxilaprevir) – July 18, 2017 – The U.S. Food and Drug Administration approved Vosevi™ to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without… Read more »

  • Clinical Insights: July 14, 2017

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval No new updates.   New Indication Approval Blincyto® (blinatumomab) – New Expanded Indication Approval – July 11, 2017 – Amgen announced that the U.S. Food and Drug… Read more »

  • Clinical Insights: June 23, 2017

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Bevyxxa™ (betrixaban) – June 23, 2017 – The U.S. Food and Drug Administration approved betrixaban (Bevyxxa™, Portola) for the prophylaxis of venous thromboembolism (VTE) in adult patients… Read more »

  • Clinical Insights: June 16, 2017

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Fibryna® (fibrinogen – [human]) – June 7, 2017 – A human fibrinogen concentrate indicated for the treatment of acute bleeding episodes in adults and adolescents with congenital… Read more »